David A. Siegel Spruce Biosciences, Inc. Transaction History

Two Sigma Advisers, LP

$42.8 Billion
Q1 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Spruce Biosciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 12,200 shares of SPRB stock, worth $732. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,200

Previous 13,800 11.59%

Holding current value

$732

Previous $5,000 40.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.29 - $0.43 $463 - $688	-1,600 Reduced 11.59%	12,200 $3,000
Q4 2024 Feb 14, 2025	SELL	$0.38 - $0.59 $5,054 - $7,847	-13,300 Reduced 49.08%	13,800 $5,000
Q3 2024 Nov 14, 2024	SELL	$0.42 - $0.59 $7,812 - $10,974	-18,600 Reduced 40.7%	27,100 $12,000
Q2 2024 Aug 14, 2024	SELL	$0.51 - $0.85 $22,746 - $37,910	-44,600 Reduced 49.39%	45,700 $23,000
Q1 2024 May 15, 2024	SELL	$0.7 - $5.49 $3,709 - $29,097	-5,300 Reduced 5.54%	90,300 $71,000
Q4 2023 Feb 14, 2024	SELL	$1.04 - $2.93 $728 - $2,051	-700 Reduced 0.73%	95,600 $280,000
Q3 2023 Nov 14, 2023	SELL	$2.04 - $2.54 $293,148 - $364,998	-143,700 Reduced 59.88%	96,300 $217,000
Q2 2023 Aug 14, 2023	BUY	$1.92 - $2.6 $388,608 - $526,240	202,400 Added 538.3%	240,000 $516,000
Q1 2023 May 15, 2023	BUY	$1.15 - $3.17 $43,240 - $119,192	37,600 New	37,600 $83,000
Q4 2021 Feb 14, 2022	SELL	$2.33 - $5.74 $44,736 - $110,208	-19,200 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$6.01 - $11.26 $115,392 - $216,192	19,200 New	19,200 $115,000

Others Institutions Holding SPRB

# of Institutions

Shares Held

15.2M

Call Options Held

Put Options Held

View Full List

About SPRUCE BIOSCIENCES, INC.

Ticker SPRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,560,200
Market Cap $1.41M
Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...

More about SPRB

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account